Corcept Therapeutics INC Form 4 insider transactions

Joseph Douglas Lyon, Corcept Therapeutics' Chief Accounting & Technology Officer, was granted 140,000 stock options with an exercise price of $35.70.

Corcept Therapeutics CEO Joseph K. Belanoff was granted 460,000 stock options with a $35.7 exercise price, vesting over four years.

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, was granted 140,000 stock options with an exercise price of $35.70.

Corcept Therapeutics granted its President of Endocrinology, Sean Maduck, 140,000 stock options with a $35.7 exercise price, vesting over four years.

Corcept Therapeutics' Chief Scientific Officer, Hazel Hunt, was granted 140,000 stock options with an exercise price of $35.70, vesting over four years.

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, was granted 140,000 stock options with an exercise price of $35.70, vesting over four years.

Corcept Therapeutics' Chief Development Officer, William Guyer, was granted 140,000 stock options with an exercise price of $35.7 per share, vesting over four years.

Corcept Therapeutics director James N. Wilson exercised stock options and transferred a significant block of shares to a family trust.

Sean Maduck, President of Corcept Endocrinology, reported several non-cash transactions involving common stock, primarily transfers between trusts and LLCs.

Corcept Therapeutics' Chief Scientific Officer, Hazel Hunt, exercised stock options and subsequently sold shares to cover the exercise cost and tax obligations.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold 20,000 shares of common stock.

Corcept Therapeutics Director G. Leonard Baker Jr. exercised 140,000 stock options, increasing his indirect beneficial ownership.

William Guyer, Corcept Therapeutics' Chief Development Officer, executed a pre-planned transaction, exercising stock options and subsequently selling 20,000 common shares.

Corcept Therapeutics Director G. Leonard Baker Jr. reported a gift of limited partnership interests affecting his indirect beneficial ownership of company common stock.

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, exercised 145,000 stock options and subsequently sold 80,284 shares to cover the exercise price and tax obligations.

Corcept Therapeutics CEO Joseph K. Belanoff exercised 550,000 stock options and transferred the resulting net shares to a revocable living trust.

Corcept Therapeutics director James N. Wilson reported significant changes in his indirect beneficial ownership of company common stock through estate planning transactions.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold a significant portion of the acquired shares under a pre-arranged 10b5-1 plan.

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported recent acquisitions of common stock through a purchase plan and restricted stock awards, alongside a disposition for tax withholding.

Corcept Therapeutics' Chief Development Officer, William Guyer, filed an amended Form 4 to correct details regarding past stock transactions and ownership.

Corcept Therapeutics' President of Endocrinology, Sean Maduck, reported exercising stock options, selling shares under a 10b5-1 plan, and acquiring new shares through a company purchase plan.

Joseph Douglas Lyon, Corcept Therapeutics' Chief Accounting & Technology Officer, exercised stock options, sold shares under a 10b5-1 plan, and acquired new shares and restricted stock awards.

Corcept Therapeutics CFO Atabak Mokari reported acquiring company shares through a purchase plan and managing tax obligations related to restricted stock unit vesting.

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock for approximately $3.19 million as part of a pre-arranged trading plan.

Corcept Therapeutics' Chief Development Officer, William Guyer, sold 4,500 shares of common stock for approximately $80.90 per share as part of a pre-scheduled trading plan.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options for 20,000 shares and subsequently sold all of them for approximately $1.5 million.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options and subsequently sold 5,000 shares of common stock under a pre-arranged 10b5-1 plan.

Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock for approximately $2.98 million in pre-scheduled transactions.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and subsequently sold 20,000 shares of Corcept Therapeutics common stock.

Corcept Therapeutics director Daniel N. Swisher Jr. exercised stock options and immediately sold 2,200 shares of common stock for $87.54 per share.